Kevin Heyeck
Chief Executive Officer & Director Chimeron Bio
Seminars
Wednesday 27th May 2026
Fireside Chat: Interrogating Next-Generation RNA Value Propositions to Define True Advantage Beyond Linear mRNA & Accelerate Clinical Adoption
9:00 am
- Clarify which benefits justify moving beyond linear mRNA, and how to differentiate next-gen RNA platforms to secure stakeholder buy-in
- Pinpoint structural reasons clinical translation has lagged expectations to avoid repeat failures and sharpen value propositions
- Define where circRNA or saRNA genuinely outperform existing modalities to strengthen investment cases and stand out in a crowded landscape
Wednesday 27th May 2026
Aligning Self-Amplifying RNA & High-Efficiency Delivery Vectors to Enable Potent, Localized In Vivo CAR-T Activity
2:00 pm
- Increase intratumoral protein levels by pairing self-amplifying RNA with a highly efficient non-LNP delivery system that drives superior cellular uptake and minimizes systemic leakage
- Unlock complex, multi-gene therapeutic designs by combining amplification capacity with a vector capable of carrying larger and multiple payloads for deeper IO impact
- Enhance tumor-selective activity and safety by generating high local expression without blood-borne exposure, enabling in vivo CAR-T mechanisms previously unattainable with LNP or linear mRNA
